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 Precis: Obstetric blood transfusions continue to increase, with most of these occurring in 
the birth admission in association with hemorrhage.
  
 Objectives: To identify trends in transfusion rates across pregnancy and the postnatal 
period, and identify risk factors for transfusion. 
Methods: Linked hospital and birth data on all births in hospitals in New South Wales, 
Australia between 2001 and 2010 were used to identify blood transfusions for women during 
pregnancy, at birth and in the 6 weeks post partum. Poisson regression was used to identify 
risk factors for red cell transfusion in the birth admission. Separate models were fitted for 
cesarean and vaginal births. 
Results: Between 2001 and 2010 there were 12147 transfusions across 891,914 pregnancies, 
with a transfusion rate of 1.4%. The transfusion rate increased steadily from 1.2% in 2001 to 
1.6% in 2010. The majority of transfusions (91%) occurred during the birth admission, and 
81% of these transfusions were associated with a diagnosis of hemorrhage. Women with 
bleeding/platelet disorders(vaginal RR= 7.8, CI 7.1-8.5, cesarean RR 8.7, CI 7.9-9.5) and 
placenta previa(vaginal RR=4.6, CI 3.7-5.8, cesarean 5.7, CI 5.2-6.2), were at highest risk of 
transfusion. Among vaginal births, increased risk was evident for forceps (RR=2.8, CI 2.6-
3.0) or vacuum births (RR=1.9, CI 1.7-2.0) compared with non-operative births.  
Conclusions: Rates of obstetric blood product transfusion have increased by 33% since 2001, 
with the majority of this associated with hemorrhage. Women with bleeding/platelet disorders 
and placenta previa are at increased risk of transfusion, and should be managed accordingly. 
 
  
 Introduction  
Blood transfusion, as applies to any therapy, should be used judiciously and appropriately to 
ensure optimal patient outcomes. Blood is a limited, costly resource with transfusion of it or 
any of its products associated with specific risks.(1, 2) Internationally, this has lead to 
increased efforts to reduce unnecessary blood use across many disciplines.(3) Transfusion of 
red blood cells generally has decreased in Australia in recent years,(4) however there is 
evidence of increasing rates of maternal red blood cell transfusion around childbirth.(5) This 
trend has also been observed in the USA, Canada, Finland, and the Republic of Ireland, 
particularly in the context of postpartum hemorrhage (PPH).(6-11) The obstetric blood 
transfusion rate in New South Wales (NSW), Australia in 2002 was 0.9%, which was higher 
than contemporaneous rates reported in other countries, including the USA (0.46% in 
2003),(7) Canada (0.63% in 2004)(12) and Ireland (0.84% in 2003).(11) Reasons for the 
higher rate are unknown, although may relate to differences in data collection. While for 
many surgical procedures, high risk of transfusion is known in advance, and measures to 
minimize the risk of transfusion can be taken, this is rarely the case in obstetrics, where 
transfusions tend to be urgent, unpredictable, and in otherwise healthy women.(13)  
A small number of population based studies have identified risk factors for blood transfusion 
in the maternity setting. Important risk factors include mode of delivery, placenta previa, 
antepartum hemorrhage, anemia, multiple pregnancies, and the extremes of maternal age.(10, 
14, 15) Population data collected in administrative datasets provide a valuable source of data 
for such studies, allowing examination of trends and risk factors in uncommon outcomes such 
as transfusion.(16) These studies typically look only at the birth admission, and so are unable 
to estimate the transfusion burden associated with antenatal and postpartum hospitalizations. 
Few studies have considered blood products other than red cells.  
This study aims to explore recent trends in blood and blood product transfusion, and the use 
of blood products throughout pregnancy and the postnatal period in women whose pregnancy 
  
 ended in a registered birth (beyond 20 weeks gestation). We also examine the risk factors 
for transfusion during the birth admission. 
Materials and Methods 
The study population included women giving birth in NSW hospitals between January 2001 
and December 2010. NSW is the most populous state in Australia, with over 7 million 
residents and approximately 90,000 births per annum. ‘Birth data’ including maternal 
characteristics, pregnancy and birth were obtained from the Perinatal Data Collection (PDC). 
The PDC is a statutory population based collection of all births in NSW of at least 20 weeks 
gestation or 400 grams birthweight. These data were linked to ‘hospital data’ from the 
Admitted Patients Data Collection (APDC). The APDC is a census of all public and private 
hospital separations in NSW, and records information on diagnoses and procedures 
associated with these separations. Up to 20 of the 55 available diagnoses and procedures for 
each separation are coded according to the 10th revision of the International Classification of 
Diseases, Australian Modification (ICD-10-AM) and the Australian Classification of Health 
Interventions (ACHI). The NSW Centre for Health Record Linkage performed probabilistic 
data linkage between the two data sets. For this study, rates of incorrect and missed links 
were less than 5 per 1000. 
Hospital admissions were classified as antenatal, birth or postnatal, to allow for examination 
of the different blood product usage at each stage of pregnancy. Antenatal admissions were 
those that occurred from 20 weeks gestation and ended with the mother being discharged 
prior to the birth. Birth admissions were separated into those with a prolonged antenatal 
component (>4 days), and those admitted 4 days or less before birth. Postnatal admissions 
were admissions occurring after the initial discharge of the mother, but within 6 weeks of the 
birth. Admissions involving transfusion of blood products were identified from the hospital 
data, using ACHI procedure codes.(17) ‘Blood transfusion’ refers to the administration of 
packed red cells or whole blood, and ‘Platelets and coagulation factors’ includes platelets, 
  
 coagulation factors, and other serum (including fresh frozen plasma), ‘Blood products’ is 
used to refer to transfusion of either or both of these. Blood transfusion and administration of 
platelets and coagulation factors are well ascertained in the hospital data, with sensitivities 
and specificities of 83.1%, 99.9% and 73.1%, 100% respectively.(16) The quality of 
reporting of use of other blood derived products (including leukocytes, gamma globulin) is 
unknown and so use of these products was not considered. Women with iron deficiency 
anemia were identified from the hospital data and women with bleeding or platelet disorders 
were identified by ICD-10-AM codes for conditions such as thalassemia, hemolytic and 
aplastic anemias, coagulation defects, and idiopathic thrombocytopenic purpura (Appendix 
1). Antepartum hemorrhage (APH) included placental abruption or other antepartum 
hemorrhage. Women without bleeding disorders, APH, placenta previa, hypertension and 
diabetes were considered to have no prior indication for transfusions. Age and gestational age 
groups were determined based on clinical relevance and women were classified as private 
patients if they received private obstetric care in a public or private hospital.  
Rates were calculated per 100,000 pregnancies and proportions are proportion of 
pregnancies, unless otherwise specified. Multiple births (twins or higher order multiples) 
were counted as a single pregnancy. Trends were assessed using the Cochran Armitage test 
for trend. A multivariable Poisson regression model with robust variances was used to 
identify factors associated with higher use of blood product transfusions; factors which were 
significant with alpha 0.2 in a univariate model were included in the initial multivariable 
model, and removed in a stepwise fashion until only variables significant at alpha 0.05 
remained. This was performed separately for vaginal and cesarean births to account for 
possible differences in decision making based on physical location (operating theatre versus 
birth unit), and differing criteria for PPH (a common indication for blood transfusion). In the 
ICD-10-AM PPH is defined as blood loss of 750mL or more following cesarean section, or 
≥500mL following vaginal birth.(18) Women with missing data on possible confounders 
were excluded from this analysis. All analyses were performed in SAS 9.3. Ethical approval 
  
 was obtained from the NSW Population and Health Services Research Ethics Committee. 
Results  
In the period 2001-2010, there were 891,914 pregnancies to 578,207 women, involving 
1,117,939 admissions.  The blood product transfusion rate was 1.4% of pregnancies, with 
11,529 mothers receiving a transfusion in 12,147 pregnancies or the postnatal period. During 
the time period, 286 women had more than one pregnancy involving a transfusion, including 
50 (17%) women with a bleeding disorder. Blood products were transfused in 484 antenatal 
admissions, 667 prolonged birth admissions, 10,715 birth and 600 postnatal admissions. The 
transfusion rate was highest for the birth admission (1201 per 100,000 pregnancies), 
compared with the antenatal (54 per 100,000 pregnancies), prolonged birth admissions (75 
per 100,000 pregnancies) and postnatal admissions (67 per 100,000 pregnancies).  Ninety-one 
percent (11382) of transfusions occurred in the birth admission, while 3.9% were antenatal 
and 4.8% were postnatal transfusions. 
The transfusion of blood products at any stage during pregnancy, birth or the postnatal period 
increased steadily from 1174 per 100,000 in 2001 to 1634 per 100,000 in 2010 (p=<0.001) 
(Figure 1). When considering only the birth admission, the rate increased from 1101 per 
100,000 in 2001 to 1532 per 100,000 in 2010 (p<0.001). There has been little change in the 
type of products used, with the majority of women (86%) receiving only packed red cells 
and/or whole blood; packed cells making up the majority of this (99.4%).  
When compared with red cell use, platelets and coagulation factors were more commonly 
used among women aged 35 and older, private patients, multiparous women and those having 
a cesarean birth (Table 1). Where blood product transfusion occurred during pregnancy, this 
usually occurred in a single admission (98.6%), with less than 0.4% of pregnancies involving 
3 or more admissions involving transfusions.  
Rates of transfusion in the birth and postnatal period were high in women having a 
hysterectomy in the birth admission (89619 per 100,000 such pregnancies, N= 439), where 
  
 blood products had been transfused antenatally (18750 per 100,000, N=63), and where a 
PPH occurred in the birth admission (13528 per 100,000, N=8388). In women with no prior 
indication, the transfusion rate was 953 per 100,000 pregnancies (N=6927). Among birth 
admissions with <4 days antenatal stay involving transfusion, 80.8% included a hemorrhage 
diagnosis. Women who received transfusions in birth or postnatal admission were in hospital 
longer than those who did not (median days (IQR) birth 5 (4,7) vs 3 (2,5), postnatal 3 (2,5) vs 
2 (0,3)).  
Full data on possible confounders were available for 885,389 pregnancies (99.3%) and were 
included in our risk factor analysis. Overall, after adjusting for maternal factors, forceps 
delivery was associated with the highest risk of transfusion of all modes of birth when 
compared with non-instrumental vaginal delivery, followed by intrapartum cesarean section, 
vacuum delivery and pre-labor cesarean section (Table 2).  Across both vaginal and cesarean 
births women with bleeding/platelet disorders or placenta previa were at increased risk of 
transfusion. Amongst vaginal births, forceps deliveries and multiple births were also 
associated with a more than doubling of the risk of transfusion, while amongst cesarean 
deliveries preterm births of <33 weeks gestation and antepartum hemorrhage were associated 
with a more than doubling of risk. Nulliparous women were at greater risk of transfusion 
when delivering vaginally, as were women with a previous cesarean (Table 2). 
When included in the model, iron deficiency anemia was associated with an increased risk of 
transfusion (vaginal RR 7.1 (6.4,7.9); cesarean RR  4.5(3.9,5.6)), leaving other estimates 
largely unchanged. However, identification of women with iron deficiency anemia has low 
sensitivity (5.7-12.0%)(19) and so this was excluded from the final model. 
Discussion 
Transfusion of blood or blood products occurred in 1 in every 71 pregnancies in NSW 
between 2001 and 2010, with the majority of these related to hemorrhage. The majority of 
transfusions occurred during the birth admission, which is unsurprising given the large 
  
 proportion associated with PPH, which typically occur within 24 hours after birth. The 
small proportion of antenatal transfusions (4.0%) is similar to the findings of several single 
hospital audit studies which found 4-7%(20-22) of transfusions in obstetrics occur 
antenatally. Few women needed transfusion during more than one admission, or in more than 
one pregnancy. Although there are many documented risk factors for transfusion in the 
obstetrics population, the transfusion rate among women with no prior indication for blood 
transfusion was 1.0%, indicating that transfusion in otherwise healthy women is not 
uncommon. 
Over the last 10 years there has been an increase in the use of blood and blood products 
throughout pregnancy, from one woman in every 85 pregnancies in 2001 to one woman in 
every 61 pregnancies in 2010. Obstetric patients use a small proportion of the blood supply 
overall (3-4%),(23) however, there is potentially increasing demand in this sub-population at 
a time when resources are becoming more limited.(1) One possible explanation for the 
increase is the changing maternal population, with more older mothers, women with previous 
cesarean sections, and having more comorbid conditions,(6, 11) however we found that the 
trend persisted when changes in these factors were taken into account.  This is similar to the 
finding of Kuklina et al. who used the United States National Inpatient Sample to examine 
changes in maternal morbidity between 1998-2005, and found an increasing trend in 
transfusion persisted, despite adjustment for confounders.(7) This may reflect a change in 
clinician behavior in treating higher risk women.  
Another possible reason for the increase in transfusion is the recent increase in PPH, which 
has been observed both in NSW(24) and overseas.(6, 8, 11, 12) As the majority of 
transfusions are performed in admissions with a diagnosis of hemorrhage, an increase in PPH 
would likely lead to an increase in blood transfusions, as has been observed elsewhere.(8, 9) 
Similar to transfusion generally, this increase in PPH is not able to be fully accounted for by 
the change in maternal characteristics.(12, 24) The increase in transfusion is also possibly 
  
 linked to increased severity of PPH.  In both Ireland and Canada there have been reports of 
increasing severity of PPH.(9, 11) 
The increase in transfusion rates may also reflect a change in practice, with clinicians using 
less restrictive criteria for transfusion than in the past, rather than reflecting an increase in 
severity of bleeding. We were unable to assess changes in transfusion thresholds, however 
there has been growing awareness of risks associated with transfusion, and concerns over the 
future availability and cost of blood.(1, 2) Against this background, it would be expected that 
changing practice should reduce rather than increase transfusion rates. Interestingly, the slight 
dip in transfusion rates in 2008 coincided with a statewide initiative to decrease obstetric 
transfusions,(25) however this decline was not maintained.  
Similar to other studies, we found increased risk of transfusion associated with bleeding and 
platelet disorders,(26) placenta previa,(15, 27) antepartum hemorrhage,(10, 15) multiple 
births,(28) primparous women,(10, 27, 28) large birthweight,(10, 28) and maternal 
hypertension.(10, 15) Vaginal birth after cesarean carried a higher risk of transfusion than 
repeat cesarean.(10, 15, 28) Preterm birth was also associated with higher rates of 
transfusion, which has been demonstrated elsewhere,(27) and is possibly related to anemia 
which is a risk factor for preterm birth and transfusion.(29) It should be noted that while 
bleeding and platelet disorders were associated with seven to nine times the risk of 
transfusion, the overall population burden of this group is small, due to the rarity of these 
conditions.  
We found both instrumental and cesarean delivery were associated with an increased risk of 
transfusion. There were higher transfusion rates following forceps deliveries than vacuum 
deliveries, and higher rates following intrapartum than pre-labor cesarean sections. Cesarean 
section had higher risk of transfusion than non-instrumental vaginal delivery, as has been 
reported elsewhere,(10, 15, 27) with this risk increased if the cesarean section was performed 
after the onset of labor. A Danish study, however, found that planned cesarean section had a 
  
 lower risk of transfusion than a planned vaginal birth, although the ‘planned vaginal birth’ 
group included women who had instrumental births and intrapartum cesarean sections.(28)  
We found the rate of transfusion to be much lower in private hospitals compared with public, 
which is consistent with lower risk women giving birth in appropriate settings. (30-32) In 
Australia, tertiary obstetric care is only available in public hospitals. Tertiary hospitals had 
the highest rates of transfusion of platelets and coagulation factors, which may reflect 
increased complexity of cases in these hospitals. Alternatively higher blood product use in 
tertiary settings could reflect better access to products in the larger centers. Blood product use 
was more common with older mothers, private patients (particularly those in public 
hospitals), multiparous women and those having a cesarean birth. Without information on 
severity of bleeding it is difficult to know the significance of these findings. Platelets and 
coagulation factors are usually transfused in cases of severe bleeding in order to replace lost 
clotting factors,(33) and are typically included as part of a massive transfusion protocol.(34) 
The increased use of blood products observed may reflect increased severity of hemorrhage 
amongst these women.  
This study reflects the population burden of blood and blood product use in obstetrics in 
Australia. The use of longitudinally linked data means allowed for the examination of blood 
product use within pregnancy, and over subsequent pregnancies. Validated and reliably 
collected information was available in either dataset. The large number of women in the 
sample allowed for adjustment by a range of risk factors.  Use of administrative datasets 
however has limitations. It lacks clinical detail, such as quantity of blood transfused, 
indication for transfusion and hemoglobin measurements. While this information would 
provide insight into the severity of cases requiring transfusion, the available data are 
sufficient to highlight risk factors and numbers of women exposed to transfusion. Anemia is 
not well reported in the hospital data, capturing only the most severe cases when such a 
diagnosis would have affected the hospital stay.(18) This would cause an overestimation of 
  
 the transfusion risk associated with anemia, however results seen here are consistent with 
those reported elsewhere for severe anemia. 
Obstetric transfusion represents a small proportion of overall blood use, however use of blood 
in obstetrics is rising and there is potential for this to continue as PPH rates continue to 
increase. Principles of patient blood management such as the prompt recognition of 
underlying coagulopathies, understanding of the pathophysiology, and the use of point of care 
testing and measurement of fibrinogen levels in the setting of acute hemorrhage will be 
important in reducing transfusion rates. As it has not been possible in this study to determine 
the exact indications and “triggers” for red cell transfusions it is difficult to opine as to the 
appropriateness of many of the transfusions, especially in the non bleeding group. Clearly, in 
exsanguinating hemorrhage transfusion is essential and a life-saving measure with questions 
revolving more around hemodynamic and coagulopathic parameters. On the other hand, in 
hemodynamically stable patients in whom hemorrhage has been controlled or is not the 
problem, the issues of patient blood management and transfusion are different. Tolerance of 
anemia in young healthy women without comorbities is important. The implementation of 
therapy, such as IV or oral iron will expedite hemopoietic recovery. Some reduction in 
transfusion rates may be possible through increased awareness surrounding the differing 
transfusion risk associated with mode of delivery, and through targeting treatment of anemia 
during pregnancy. Additional reduction in blood use may be achievable through exploring 
variation in blood use between hospitals.  
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 Figure Legends 
Figure 1 Rate of transfusions per 100,000 births, NSW 2001-2010* 
 
*this includes any transfusion during the antenatal period, birth admission and postnatally. 
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Appendix 1: ICD10 AM and procedure codes for selected conditions and procedures 
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  Table 1 Characteristics of pregnancies by blood product transfusion status during pregnancy, NSW 2001-2010. 
  Variable Packed red 
cells/blood 
Platelet/ Coagulation 
Factors 
Any Blood 
products 
No Blood 
products 
Rate per 100,000 
births 
Total  Pregnancies 11760 (100.0) 1648 (100.0) 12147 (100.0) 879767 (100.0) 1362 
Maternal age  
  
<20 years 612 ( 5.2) 42 ( 2.5) 626 ( 5.2) 33500 ( 3.8) 1834 
20-34 8392 ( 71.4) 1084 ( 65.8) 8682 ( 71.5) 658286 ( 74.8) 1302 
35+ 2756 ( 23.4) 522 ( 31.7) 2839 ( 23.4) 187981 ( 21.4) 1488 
Private patient  
  
Yes 2602 ( 22.1) 472 ( 28.6) 2724 ( 22.4) 296410 ( 33.7) 911 
No 9158 ( 77.9) 1176 ( 71.4) 9423 ( 77.6) 583357 ( 66.3) 1590 
Smoker Yes 1963 ( 16.7) 197 ( 12.0) 2002 ( 16.5) 121511 ( 13.8) 1621 
No 9767 ( 83.1) 1442 ( 87.5) 10113 ( 83.3) 756086 ( 85.9) 1320 
Multiple birth  
  
Yes 612 ( 5.2) 92 ( 5.6) 631 ( 5.2) 13383 ( 1.5) 4503 
No 11148 ( 94.8) 1556 ( 94.4) 11516 ( 94.8) 866384 ( 98.5) 1312 
Nullipara Yes 5608 ( 47.7) 738 ( 44.8) 5812 ( 47.8) 369525 ( 42.0) 1548 
No 6136 ( 52.2) 907 ( 55.0) 6317 ( 52.0) 509032 ( 57.9) 1226 
Previous Cesarean  
  
Yes 1726 ( 14.7) 361 ( 21.9) 1792 ( 14.8) 119573 ( 13.6) 1477 
No 10034 ( 85.3) 1287 ( 78.1) 10355 ( 85.2) 760194 ( 86.4) 1344 
  
 
Bleeding/platelet 
Disorders  
Yes 1132 ( 9.6) 291 ( 17.7) 1275 ( 10.5) 7713 ( 0.9) 14186 
No 10628 ( 90.4) 1357 ( 82.3) 10872 ( 89.5) 872054 ( 99.1) 1231 
Antepartum 
Hemorrhage  
Yes 1045 ( 8.9) 238 ( 14.4) 1084 ( 8.9) 22179 ( 2.5) 4660 
No 10715 ( 91.1) 1410 ( 85.6) 11063 ( 91.1) 857588 ( 97.5) 1274 
Placenta Previa 
  
Yes 962 ( 8.2) 228 ( 13.8) 979 ( 8.1) 8485 ( 1.0) 10344 
No 10798 ( 91.8) 1420 ( 86.2) 11168 ( 91.9) 871282 ( 99.0) 1266 
Iron deficiency 
Anemia 
Yes 772 ( 6.6) 56 ( 3.4) 778 ( 6.4) 4725 ( 0.5) 14138 
No 10988 ( 93.4) 1592 ( 96.6) 11369 ( 93.6) 875042 ( 99.5) 1283 
Gestational age (at 
birth)  
  
20-32 736 ( 6.3) 207 ( 12.6) 791 ( 6.5) 13436 ( 1.5) 5560 
33-36 1182 ( 10.1) 283 ( 17.2) 1266 ( 10.4) 42836 ( 4.9) 2871 
37+ 9842 ( 83.7) 1158 ( 70.3) 10090 ( 83.1) 823495 ( 93.6) 1210 
Delivery type  
  
  
  
Normal vaginal 5226 ( 44.4) 491 ( 29.8) 5341 ( 44.0) 537476 ( 61.1) 984 
Cesarean 4343 ( 36.9) 947 ( 57.5) 4588 ( 37.8) 246130 ( 28.0) 1830 
    Pre-labor CS 2319 ( 19.7) 583 ( 35.4) 2484 ( 20.4) 141349 ( 16.1) 1727 
   Intrapartum CS 2023 ( 17.2) 364 ( 22.1) 2103 ( 17.3) 104779 ( 11.9) 1968 
Instrumental 2176 ( 18.5) 206 ( 12.5) 2202 ( 18.1) 96308 ( 10.9) 2235 
  
 
    Forceps 1068 ( 9.1) 102 ( 6.2) 1081 ( 8.9) 32663 ( 3.7) 3204 
    Vacuum 1108 ( 9.4) 104 ( 6.3) 1121 ( 9.2) 63645 ( 7.2) 1731 
Induction 
  
Yes 3794 ( 32.3) 540 ( 32.8) 3910 ( 32.2) 236932 ( 26.9) 1623 
No 7966 ( 67.7) 1108 ( 67.2) 8237 ( 67.8) 642835 ( 73.1) 1265 
Birthweight (for 
gestation) 
Small 895 ( 7.6) 165 ( 10.0) 959 ( 7.9) 83218 ( 9.5) 1139 
Average 9039 ( 76.9) 1294 ( 78.5) 9333 ( 76.8) 703661 ( 80.0) 1309 
LGA 1826 ( 15.5) 189 ( 11.5) 1855 ( 15.3) 92888 ( 10.6) 1958 
Hospital of birth  
  
Tertiary 5934 ( 50.5) 982 ( 59.6) 6157 ( 50.7) 358695 ( 40.8) 1688 
Regional 2844 ( 24.2) 210 ( 12.7) 2906 ( 23.9) 188394 ( 21.4) 1519 
Urban/other 1488 ( 12.7) 182 ( 11.0) 1522 ( 12.5) 119278 ( 13.6) 1260 
Private 1494 ( 12.7) 274 ( 16.6) 1562 ( 12.9) 213400 ( 24.3) 727 
Denominator=Pregnancies
  
 Table 2 Factors associated with blood or blood product transfusion in the birth admission, NSW 2001-2010. 
 Vaginal deliveries Cesarean Deliveries 
Univariate model Multivariable model Univariate model Multivariable model 
RR 95% CI RR 95% CI RR 95% CI RR 95% CI 
Maternal age Under 20 1.4 (1.27,1.55) 1.2 (1.05,1.29) 1.8 (1.51,2.08) 1.5 (1.27,1.75) 
20-35 1.0  1.0  1.0  1.0  
35+ 1 (0.97,1.09) 1.1 (1.02,1.16) 1.2 (1.09,1.24) 1.2 (1.09,1.25) 
Private Patient 0.6 (0.56,0.63) 0.8 (0.70,0.84) 0.5 (0.44,0.50) 0.8 (0.69,0.84) 
Smoker 1.1 (1.02,1.17) 1.1 (1.07,1.22) 1.5 (1.40,1.65) 1.1 (1.00,1.18) 
Australian born 0.8 (0.78,0.86) 0.8 (0.76,0.85) 0.9 (0.80,0.91) 0.9 (0.81,0.93) 
Multiple birth 4.3 (3.78,4.86) 2.8 (2.47,3.26) 2.5 (2.23,2.75) 1.7 (1.50,1.91) 
Nullipara 1.7 (1.59,1.74) 1.4 (1.35,1.51) 0.8 (0.78,0.88) 0.7 (0.62,0.72) 
Previous Cesarean 1.5 (1.37,1.69) 1.8 (1.63,2.02) 0.7 (0.62,0.71) 0.7 (0.68,0.80) 
Bleeding/platelet disorder 9.6 (8.77,10.4) 7.8 (7.11,8.48) 11.4 (10.51,12.35) 8.7 (7.93,9.50) 
Iron deficiency anemia 9.1 (8.22,10.07)     9.4 (8.35,10.52)   
Chronic Hypertension 1.6 (1.31,2.05)     1.5 (1.25,1.86)   
Pregnancy hypertension 2 (1.88,2.15) 1.6 (1.48,1.70) 1.7 (1.56,1.80) 1.5 (1.41,1.65) 
  
 
Any Diabetes 1.2 (1.11,1.35)   1.1 (0.96,1.18)   
Placenta Previa 7.3 (5.91,8.95) 4.6 (3.70,5.83) 7.3 (6.78,7.81) 5.7 (5.24,6.22) 
Antepartum Hemorrhage 2.6 (2.34,2.87) 1.9 (1.68,2.09) 4.6 (4.25,4.99) 2.2 (2.02,2.43) 
Augmentation of labor 1.5 (1.39,1.59) 1.3 (1.20,1.39) 0.9 (0.83,1.07)   
Induction 1.5 (1.47,1.61) 1.5 (1.38,1.53) 1.1 (0.98,1.14) 1.1 (1.04,1.25) 
Intrapartum CS     1.1 (1.08,1.21) 1.3 (1.24,1.43) 
Prolonged labor 2.2 (2.03,2.37)     1.6 (1.37,1.89)   
Regional analgesia 1.5 (1.40,1.55)         
Birthweight 
(for 
gestation) 
Small 0.8 (0.72,0.87) 0.7 (0.67,0.80) 0.9 (0.84,1.05) 0.8 (0.73,0.90) 
Average 1.0  1.0  1.0  1.0  
Large  1.6 (1.52,1.74) 1.7 (1.60,1.84) 1.2 (1.14,1.33) 1.3 (1.19,1.39) 
Gestational 
Age 
Under 33 weeks 3 (2.66,3.39) 1.8 (1.56,2.11) 6.1 (5.55,6.67) 2.7 (2.43,3.02) 
33-36 weeks 1.5 (1.38,1.68) 1.2 (1.06,1.30) 3.1 (2.88,3.37) 1.7 (1.57,1.87) 
37+ weeks 1.0  1.0  1.0  1.0  
Delivery 
type 
Vaginal 1.0  1.0      
Forceps 3.5 (3.26,3.72) 2.8 (2.57,2.97)     
  
 
Vacuum 1.9 (1.74,1.98) 1.6 (1.54,1.77)         
Year of birth 1.1 (1.04,1.06) 1 (1.04,1.06) 1 (1.01,1.03) 1 (1.02,1.05) 
Hospital type Tertiary  1.3 (1.19,1.37) 1.1 (1.00,1.15) 1.4 (1.27,1.56) 1.1 (0.96,1.18) 
Metropolitan  1.0  1.0  1.0  1.0  
Regional 1.2 (1.09,1.28) 1.2 (1.14,1.34) 1.2 (1.09,1.37) 1.3 (1.12,1.42) 
Private hospitals 0.6 (0.54,0.65) 0.6 (0.55,0.70) 0.5 (0.41,0.52) 0.6 (0.56,0.75) 
Reference categories are absence of risk factor unless otherwise specified 
 
 
